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Dengue is a mosquito-borne viral disease
caused by one of four antigenically distinct
dengue flaviviruses: DEN-1, DEN-2, DEN-3, and
DEN-4. Primary infection with any serotype may
lead to acute illness defined as fever with two or
more of the following symptoms: headache,
retroorbital pain, myalgia, arthralgia, rash, and
hemorrhagic manifestations (1,2). Fever and
other symptoms may subside after 3 or 4 days,
and the patient may recover completely, or the
fever may return with a rash within 1 to 3 days (3).
Secondary exposure to the same serotype
generally does not produce illness because of pre-
existing antibodies. However, secondary expo-
sure to a different serotype may lead to another
dengue fever episode, and the patient may be at
risk for more serious forms of infection, dengue
hemorrhagic fever (DHF) or dengue shock
syndrome (DSS) (3). Dengue virus infection may
also cause a nonspecific febrile illness that can be
easily confused with measles or influenza.
Therefore, laboratory testing is essential to
clinical diagnosis and public health reporting.
Dengue-viremic persons are usually infec-
tious to the mosquito vector 1 day before the
onset of the febrile period and remain so for 6-7
days. When a mosquito ingests virus in a blood
meal, the virus replicates during an extrinsic
incubation period of 8 to 12 days, after which the
mosquito remains infective for life (4,5). The life
span of Aedes aegypti, the primary vector of
dengue in the Americas, is usually 21 days,
although life span and incubation periods
depend on temperature and rainfall (6). Both
A. aegypti and A. albopictus, a recently
introduced vector species (7), have been found
throughout Florida, and A. aegypti breeds year-
round in south Florida (8).
The last dengue epidemics in Florida, in the
Tampa and Miami areas in 1934-35 (9,10),
affected an estimated 15,000 of the 135,000
population of Miami. The last recorded epidemic
in the southeastern states was in Louisiana in
1945 (11). Most cases of dengue reported in the
United States since the 1940s have been
imported; however, indigenous transmission of
dengue occurred in Texas in 1986 and 1995
(8,12-14). In response to an outbreak of dengue in
Mexico in 1995, the Texas Department of Health
initiated an active surveillance program that
detected 29 confirmed cases, including seven in
persons with no recent history of travel outside
Texas (14,15). Thirteen imported dengue cases (0
to 4 cases per year) were reported in Florida from
1985 to 1995 (16).
The recent introduction of DEN-3 in Mexico
and Central America is of public health
importance because most of the population in the
tropical Americas is susceptible to infection with
this serotype (17,18). The presence of the vector,
the rapid spread of the virus, and increased air
travel and immigration contribute to the
possibility of future dengue transmission in the
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continental United States (19-21). A serosurvey
conducted after the first confirmed dengue
outbreak in Peru in 1990 clearly demonstrated
earlier undetected dengue transmission (22).
Silent transmission of dengue was also
demonstrated in 1992 in an area of Taiwan
believed free of the disease (23). In both cases, an
early warning system based on immunoglobulin
(Ig)M antibody-capture enzyme-linked immun-
osorbent assay (MAC-ELISA) laboratory tests
was recommended for disease monitoring. Active
surveillance, an essential component of an early
warning system for detection of dengue, provides
information vital to defining epidemiologic
aspects of cases and enabling educational and
mosquito control efforts (24-27).
Recent outbreaks of dengue in nearby
Caribbean and Central and South American
countries may increase the likelihood of future
autochthonous transmission in Florida (15).
Mosquito vectors are widely distributed in the
state, and travelers returning from dengue-
endemic areas place at risk the resident
population, which has minimal (if any) immunity
to dengue viruses. Because physicians’ aware-
ness of dengue is low and specialized laboratory
diagnostic methods are not available locally, low-
level dengue transmission may go undetected.
Imported dengue may thus be underreported in
Florida, which has relied on passive surveil-
lance. We used an educational campaign for
county epidemiologists and health-care provid-
ers and an active laboratory-based surveillance
program that facilitated prompt, accurate
diagnosis of dengue to assess the risk for local
dengue fever transmission in Florida.
The Study
The first phase of the surveillance program
was the design of a dengue information packet
for all 67 county health department epidemiolo-
gists in Florida, to be distributed to hospital
emergency rooms, clinics, health departments,
and infectious disease physicians in the county.
The letter included information on case
reporting, the dengue case definition, specimen
requirements and transport instructions, and a
dengue case investigation form.
Under cooperative agreements with two
Florida commercial clinical laboratories (na-
tional reference clinical laboratories), specimens
from patients with suspected dengue were
forwarded to the state laboratory for free testing.
In cases where specimens were tested at
commercial laboratories only, dengue antibody-
positive results were forwarded to county health
departments and to the state laboratory for
inclusion in this study. In Florida, dengue
testing is offered only by the state laboratory and
some commercial clinical laboratories.
Before this study, the hemagglutination
inhibition (HAI) assay was the only serologic test
for dengue offered at the state laboratory.
Laboratory capabilities were enhanced to include
testing for IgM antibodies to dengue. Acute- and
convalescent-phase serum specimens were
tested for dengue antibodies by both HAI assay
and MAC-ELISA, using a DEN1-4 serotype
cocktail (28-30). Available specimens positive for
IgM antibodies to dengue, tested at the Florida
state laboratory, were forwarded to CDC’s Dengue
Branch laboratory for virus isolation, serotyping,
and confirmation of serologic results.
Cases were classified as DHF if all the
following were present: fever, hemorrhagic
tendencies, thrombocytopenia (100,000/mm3 or
less), and evidence of plasma leakage (hemat-
ocrit level increased by > 20%) or other objective
evidence of increased capillary permeability (31).
If all the above were present, plus hypotension or
pulse pressure < 20 mm Hg, the case was
classified as DSS.
In this study, a case was classified as
presumptive dengue on the basis of serologic
evidence of an HAI titer > 1:1280, an equivalent
IgG titer, or a positive dengue IgM antibody test
on a single serum sample. A confirmed dengue
case required a fourfold rise in HAI, IgG, or IgM
antibody titers between acute- and convalescent-
phase serum specimens; isolation of virus; or
detection of viral antigen by immunohistochem-
istry, immunofluorescence, or viral nucleic acid
detection. Confirmed or presumptive dengue cases
are referred to as laboratory-diagnosed cases.
A case was classified as undetermined if
sufficient information was not available on the
timing of specimen collection in relation to onset
of symptoms or a convalescent-phase serum was
not available to demonstrate a fourfold rise in
antibody titers. A case was also considered
undetermined if the acute-phase serum was
negative for antibodies and a convalescent-phase
serum was not available.
Epidemiologic data were obtained from
dengue case investigation forms that accompa-
nied the patients’ specimens. Suspected as well32 32 32 32 32 Emerging Infectious Diseases Vol. 6, No. 1, January–February 2000
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Table 2. Laboratory-diagnosed dengue cases in
Florida by county, area of travel, and serotype, April
1997 and March 1998
Area of travel – number of cases
          (dengue serotype)
County                   (n = 18)
Broward Barbados – 1
Dade Colombia – 1
Haiti – 3
Puerto Rico – 1 (DEN-2)
Venezuela – 2 (DEN-1)
Unknown – 1
Hillsborough Colombia – 1 (DEN-2)
Nicaragua – 1 (DEN-3)
Thailand – 1
Unknown – 1
Orange Haiti – 2 (DEN-4)
Puerto Rico – 1
Palm Beach Haiti – 1
Puerto Rico – 1
Figure 1. County of residence for 18 laboratory-
diagnosed dengue cases detected between April
1997–March 1998.
Table 1. Characteristics of 83 suspected cases of
dengue investigated in Florida, April 1997–March 1998
Undeter-
Characteristic  Yes   No mined
History of recent travel to   41   14    28
  to dengue-endemic area (49%) (17%)  (34%)
Fits dengue fever case   30     8    45
 definition (36%) (10%)  (54%)
Flavivirus antibody   41   42
  detected (49%) (51%)
Convalescent-phase   25   58
  specimen provided (30%) (70%)
Laboratory confirmation   18   24    41
  of recent dengue (22%) (29%)  (49%)
  infection
as confirmed cases of dengue are reportable in
Florida (32). County health departments were
notified of suspected cases, and a convalescent-
phase serum was requested.
We used the Epi Info Software package for
data analysis (33). Comparisons were made with
historical data on reported cases of dengue
(9,16,34-36).
From April 1, 1997, to March 31, 1998, 83
suspected cases of dengue were studied. Commer-
cial clinical laboratories referred specimens for
analysis for 36 (43%) of these cases. The rest
were referred through county health depart-
ments, hospital laboratories, infection control
practitioners, or physicians. Recent dengue
infection  was laboratory diagnosed in 18 (22%) of
these cases. Twelve (67%) of the 18 confirmed
dengue specimens were referred by commercial
clinical laboratories. Virus isolation or poly-
merase chain reaction of five cases yielded all
four dengue serotypes. Dengue was ruled out as
the etiologic agent in 24 (29%) cases. The
remaining 41 (49%) cases were undetermined
because convalescent-phase serum samples were
not available (Table 1).
Most (65%) of suspected-dengue patients were
male (chi-square goodness of fit test p value =
0.006). Among suspected cases, the mean age was
41 years (1 day to 79 years). Forty-one (49%)
initially tested positive for anti-flavivirus
antibodies. Convalescent-phase serum was ob-
tained in 25 (30%) of the cases. The average age of
patients with confirmed dengue cases was 37
years (8 to 69); 14 (78%) of the 18 patients
were male.
Laboratory-diagnosed cases were identified
from five counties in central and extreme
southeastern Florida (Figure 1). Cases were
confirmed in persons residing in the following
counties: Dade (8), Hillsborough (4), Orange (3),
Palm Beach (2), and Broward (1). Table 2 lists
Florida counties with laboratory-diagnosed
dengue cases, case travel history, and dengue
virus serotypes detected. All 18 laboratory-
diagnosed dengue cases were in persons who had33 33 33 33 33 Vol. 6, No. 1, January–February 2000 Emerging Infectious Diseases
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Figure 2. Reported dengue cases in Florida,
1987–1997.
(*1997 = study year April 1, 1997–March 31, 1998)
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recently traveled to dengue-endemic areas and
were therefore classified as imported. We
included out-of-state cases in our analysis
because the acute phase of their illness occurred
while they were in Florida. Current county
health department policy dictates that only cases
in Florida residents are reported to the state
epidemiologist for recording in the weekly and
yearly morbidity statistics. Other case reports
are forwarded to the county and state of primary
residence of the patient.
Hemorrhagic manifestations were reported
in 7 (39%) of the 18 confirmed cases; one met the
DHF case definition; however, it was not possible
to classify the remaining six cases with
hemorrhage because information on hemocon-
centration and plasma leakage was incomplete.
Encephalopathy was present in one case. Antibody
titers suggested secondary dengue infections in 10
(56%) of the 18 cases. Only 2 (11%) of the 18 cases
appeared to involve primary infections. Labora-
tory tests necessary to determine infection status
(primary vs. secondary) were not available in the
other six cases. A woman with acute secondary
dengue infection with hemorrhagic manifesta-
tions gave birth to a healthy uninfected baby.
Conclusions
During the year of active surveillance, 18
laboratory-diagnosed cases of dengue were
detected. On the basis of the previous 10-year
mean of 1.3 cases per year (Figure 2), the
probability of detecting 18 cases was virtually 0%
(Poisson distribution rare event vs. standard
test). These cases were identified in Florida
counties with high rates of international travel
and large immigrant populations, as well as year-
round breeding of A. albopictus and A. aegypti
mosquitoes. According to Florida Department of
Commerce statistics, of the 6 million interna-
tional visitors to Florida in 1995, 38.4% traveled
from South and Central America, the Caribbean,
Mexico, Asia, and other tropical areas (37) in
which dengue is endemic.
All four dengue serotypes were detected in
five specimens during this study. Improved
specimen handling should increase the rate of
virus isolation. The serotype of the infecting
dengue virus was identified in only five cases for
the entire United States in 1995, when 79
laboratory-diagnosed dengue cases were docu-
mented (12). In the same year, 22 imported and
seven indigenous cases were detected in Texas
(15). In 1996, the infecting dengue serotype was
identified in 5 of the 43 laboratory-diagnosed
cases of imported dengue in the United States
(three cases of DEN-1 and two of DEN-2) (38).
This study found multiple problems with
routine clinical laboratory confirmation and
follow-up of dengue infections: Tests requested
by physicians and performed at clinical
laboratories were not always optimal for
identifying a current dengue infection. Even
though the dengue IgM test is the most
appropriate assay for determining current
infection, it is not routinely performed at
commercial laboratories and may not be readily
available if requested. Test results are fre-
quently misinterpreted, e.g., a single positive
indirect fluorescent antibody test performed at a
commercial laboratory may be interpreted as
positive for current dengue infection when it
only indicates infection with a flavivirus (e.g.,
dengue, St. Louis encephalitis, Japanese encepha-
litis) or vaccination (e.g., yellow fever) at an
undetermined time in the past. In addition, cases
are rarely investigated, and the convalescent-
phase serum samples needed for confirmation
are rarely requested. When an investigation
indicates need for further testing, specimens
may have already been discarded. Finally,
positive test results are often not forwarded to
the county and state epidemiologists in a timely
manner. In cases tested only at commercial
laboratories, delays of 2 to 4 months before
positive cases were reported to the state Bureau
of Epidemiology preclude prompt follow-up.
Three of the confirmed dengue cases in this
study tested at commercial laboratories had not34 34 34 34 34 Emerging Infectious Diseases Vol. 6, No. 1, January–February 2000
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been reported to the state epidemiologist by the
county health departments because the patients
were primary residents of other states, although
they became ill while in Florida.
This study indicates that surveillance efforts
should be concentrated in densely populated
counties with large numbers of international
travelers (Dade, Palm Beach, Orange, and
Hillsborough), especially during dengue season
in the Caribbean (July to November). As a part of
the epidemiologic investigation of imported
dengue cases, an attempt should be made to
identify secondary cases.
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